Scynexis Inc

NASDAQ:SCYX   3:59:52 PM EDT
2.13
+0.03 (+1.43%)
Products, Regulatory

SCYNEXIS Presents New Interim Positive Data Of Ibrexafungerp For Refractory Vulvovaginal Candidiasis From Ongoing Phase 3 FURI Study At The American College Of Obstetricians And Gynecologists (A

Published: 05/10/2022 13:04 GMT
Scynexis Inc (SCYX) - Scynexis Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis From Ongoing Phase 3 Furi Study at the American College of Obstetricians and Gynecologists (acog) Annual Clinical & Scientific Meeting.
Scynexis Inc - in Study, Ibrexafungerp Was Generally Safe and Well-tolerated With Findings Consistent With Existing Product Label.
Scynexis- Data Show That of Furi Study Patients With Refractory Or Relapsed Vvc Treated With Ibrexafungerp, 71.4% Had Successful Clinical Outcomes.